Apyx Medical Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue grew 32% year-over-year to $12.5M, led by AYON system sales and strong international demand. Gross margin improved to 63.5%, and full-year guidance was raised to $59–$60M. AYON adoption is early, with FDA clearance for power liposuction expected soon.
-
AYON, a fully integrated surgical aesthetics system, is driving strong growth and market interest by consolidating multiple technologies and addressing new demand from GLP-1-induced skin laxity. The company is achieving operational efficiencies, expanding internationally, and expects 17%-19% revenue growth this year.
Fiscal Year 2025
-
Record Q4 revenue and strong AYON system adoption drove 35% year-over-year growth, with positive EBITDA and improved cash flow. 2026 guidance projects continued double-digit growth in surgical aesthetics, with plans for international expansion and further product enhancements.
-
Q3 2025 revenue grew 12% year-over-year to $12.9M, driven by the AYON system launch and strong U.S. Surgical Aesthetics sales. Net loss narrowed, gross margin improved, and 2025 revenue guidance was raised, reflecting robust demand and operational efficiency.
-
GLP-1-driven demand is fueling growth in surgical aesthetics, with AON’s integrated platform delivering superior clinical outcomes, efficiency, and patient satisfaction. Surgeons report increased procedure volumes and strong interest in the upcoming power-assisted handpiece.
-
GLP-1 therapies are reshaping the aesthetics market, driving demand for skin tightening and surgical interventions. New product launches like AYON and strong Renuvion sales support raised financial guidance and global expansion, with a focus on surgeon partnerships and operational efficiency.
-
Q2 2025 revenue declined 6% year-over-year, but gross margin improved and net loss narrowed due to cost reductions. Strong demand for AYON and Renuvion, especially in new markets like China, led to raised 2025 revenue guidance. Cash position remains solid.
-
Q1 2025 revenue declined 8% year-over-year to $9.4M, but advanced energy sales grew 6% and gross margin improved to 60.1%. Cost controls reduced net loss and cash burn, and 2025 guidance was reaffirmed with the AYON launch expected in H2 pending FDA clearance.
Fiscal Year 2024
-
Q4 2024 revenue declined 3% year-over-year, but gross margin improved to 63% and net loss narrowed. Advanced energy segment showed sequential growth, while OEM sales declined. 2025 guidance projects stable revenue, strong cost controls, and a planned launch of the Aion system in H2 2025.
-
Significant cost reductions and a strong cash position set the stage for the 2025 launch of the Aion system, which integrates advanced surgical body contouring technologies. The company targets EBITDA positivity in 2026 and plans aggressive domestic and international expansion, supported by innovative adoption programs.
-
Q3 revenue declined 4% year-over-year amid macro headwinds, but disposable handpiece sales grew and cost controls reduced operating expenses. A major restructuring, new product launch, and $7M capital raise aim to extend runway and return to growth in 2025.
-
Q2 2024 revenue fell 10% year-over-year, with Advanced Energy sales down 17% but OEM sales up 29%. Handpiece sales grew over 20% globally, offsetting weak generator demand. 2024 guidance was updated, with revenue expected to be flat to down 3% and net loss guidance improved.